Skip to main content

Valliant John's Form 4 filing

Fusion Pharmaceuticals Inc. (FUSN) · filed Mar 8, 2022

Accession no.
0001209191-22-017150
Filed
Mar 8, 2022
Trade date
Mar 4-8, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $103.9K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Valliant JohnCIK 0001813574Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 4, 2022Common StockSSaleDisposed−8,400$7.32F2−$61,488396,390Direct
Mar 7, 2022Common StockSSaleDisposed−3,100$6.99F3−$21,669393,290Direct
Mar 8, 2022Common StockSSaleDisposed−3,004$6.92F4−$20,787.68390,286Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.15 to $7.53 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.95 to $7.16 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.83 to $7.07 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)